Connect with us

COVID-19

Children take part in vaccine study as Pfizer seeks FDA approval

Published

 on

(Last Updated On: October 8, 2021)

Pfizer Inc and BioNTech have asked U.S. regulators to authorize emergency use of their COVID-19 vaccine for children ages 5 to 11, a group for whom no shot is currently allowed, Pfizer said on Thursday (October 07), Reuters reported.

A trial to test vaccine safety on children took place at Duke University School of Medicine. Two of the children who took part, were 7 year old Lydia and her sister, 5 year old Bridgette.

Both of the girls were calm as they received their vaccinations, although Bridgette instructed her father to hold her hand, read the report.

The U.S. Food and Drug Administration has set a date of Oct. 26 for its panel of outside advisers to meet and discuss Pfiizer’s application, making it possible for children in this age group – numbering around 28 million – to begin receiving the two-dose Pfizer/BioNTech vaccine shortly afterward.

The vaccine already has won U.S. emergency use authorization in teens ages 12 to 15 and is fully approved by regulators for people ages 16 and up.

The Pfizer/BioNTech vaccine is one of three in use in the United States, along with the two-dose Moderna vaccine and the single-dose Johnson & Johnson version, neither of which has won full regulatory approval for any age group.

A rapid authorization of the Pfizer/BioNTech vaccine in young kids could help mitigate a potential surge of cases in the coming weeks and months, with schools open nationwide and colder weather driving activities indoors. If given regulatory authorization, the two-dose Pfizer/BioNTech vaccine would become the first COVID-19 shot made available to children 5 to 11 in the United States, Reuters reported.

COVID-19

India records spike in daily COVID cases and 21 deaths in 24 hours

Published

on

(Last Updated On: June 27, 2022)

India logged 17,073 new COVID-19 cases early Monday morning, raising its tally to 43,407,046, and 21 deaths in the past 24 hours, the health ministry reported.

The death toll now stands at 525,020.

The national COVID-19 recovery rate was 98.57 percent, the ministry said.

Pakistan’s ministry of health meanwhile reported Monday that it had recorded 382 new cases in the last 24 hours.

This took Pakistan’s COVID-19 total case count to over 1.53 million. Two deaths were also reported in the past 24 hours.

However, experts say Pakistan may potentially witness another COVID-19 wave as the country continues to see an uptick in new cases.

Continue Reading

COVID-19

Pfizer says tweaked COVID-19 shots boost omicron protection

Published

on

(Last Updated On: June 26, 2022)

Pfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is safe and works — just days before US regulators debate whether to offer Americans updated booster shots this fall.

The vaccines currently used in the US still offer strong protection against severe COVID-19 disease and death — especially if people have gotten a booster dose, AP reported.

But those vaccines target the original coronavirus strain and their effectiveness against any infection dropped markedly when the super-contagious omicron mutant emerged.

Now with omicron’s even more transmissible relatives spreading widely, the US Food and Drug Administration is considering ordering a recipe change for the vaccines made by both Pfizer and rival Moderna in hopes that modified boosters could better protect against another COVID-19 surge expected this fall and winter.

Pfizer and its partner BioNTech studied two different ways of updating their shots — targeting just omicron, or a combination booster that adds omicron protection to the original vaccine. They also tested whether to keep today’s standard dosage — 30 micrograms — or to double the shots’ strength.

In a study of more than 1,200 middle-aged and older adults who’d already had three vaccine doses, Pfizer said both booster approaches spurred a substantial jump in omicron-fighting antibodies.

“Based on these data, we believe we have two very strong omicron-adapted candidates,” Pfizer CEO Albert Bourla said in a statement.

Pfizer’s omicron-only booster sparked the strongest immune response against that variant.

Continue Reading

COVID-19

India sees surge in new COVID-19 infections

Published

on

(Last Updated On: June 23, 2022)

India’s ministry of health on Thursday reported they have seen a surge in COVID-19 cases in the country in the past 24 hours.

According to the health ministry, 13,313 new cases were recorded in the last 24 hours, compared to 12,249 cases on Wednesday.

According to the Ministry, 10,972 people have recovered from the infection which took the total number of recoveries to over 42 million.

With the recorded cases, India’s active caseload now stands at 83,990.

The ministry also said 38 people have died in the last 24 hours due to the infection, taking the total number of deaths to 524,941.

Continue Reading

Trending

Copyright © 2022 Ariana News. All rights reserved!